Sugi Predict

Sugi Predict / Compounds / SCHEMBL5408525

SCHEMBL5408525

SCHEMBL5408525

CC(C)(C)OC(=O)C[C@@H](CCCC1CCCCC1)C(=O)ONC1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 2/20 0.43
▸ HDAC4 P56524 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ GAA P10253 1/20 0.37
▸ NAAA Q02083 4/20 0.36
▸ CTSS P25774 1/20 0.36
▸ CTSK P43235 1/20 0.36
▸ BTK Q06187 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ BCHE P06276 1/20 0.35
▸ MMP2 P08253 1/20 0.35
▸ BMP1 P13497 1/20 0.35
▸ HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5408737 0.82 MMP2 (0.51) EPHX1MMP2
SCHEMBL5403076 0.81 PPARG (0.41) EPHX1HDAC4HDAC1HDAC6GAA
SCHEMBL5398181 0.81 PPARG (0.41) EPHX1HDAC4HDAC1HDAC6GAA
SCHEMBL5415566 0.80 PPARG (0.40) EPHX1HDAC4HDAC1HDAC6GAA
SCHEMBL5415572 0.80 PPARG (0.40) EPHX1HDAC4HDAC1HDAC6GAA
SCHEMBL6872894 0.80 BMP1 (0.37) EPHX1CTSSCTSKSMN1; SMN2BCHE
SCHEMBL5415569 0.79 SMN1; SMN2 (0.36) EPHX1HDAC4HDAC1HDAC6CTSS
SCHEMBL6430229 0.77 SMN1; SMN2 (0.34) EPHX1SMN1; SMN2MMP2BMP1
SCHEMBL6430228 0.77 SMN1; SMN2 (0.34) EPHX1SMN1; SMN2MMP2BMP1
SCHEMBL6872619 0.76 SMN1; SMN2 (0.36) CTSSCTSKSMN1; SMN2MMP2BMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1240152-B1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LTD (GB) 2004-12-08 — — EP claimed
US-20030119807-A1 3-Heterocyclylpropanohydroxamic acids BAILEY SIMON (US) 2003-06-26 — — US claimed
JP-2003519133-A — — 2003-06-17 — — JP claimed
EP-1240152-A1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS Pfizer Limited (GB) 2002-09-18 — — EP claimed
WO-2001047901-A1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LIMITED (GB) 2001-07-05 — — WO claimed
US-7214694-B2 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors PFIZER INC (US) 2007-05-08 — — US disclosed
EP-1343771-B1 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LTD (GB) 2006-04-12 — — EP disclosed
EP-1373231-B1 3-HETEROCYCLYL-PROPANO-HYDROXAMIC ACID AS PCP INHIBITORS PFIZER LTD (GB) 2005-06-08 — — EP disclosed
US-6897306-B2 3-heterocyclylpropanohydroxamic acids PFIZER PRODUCTS, INC. (US) 2005-05-24 — — US disclosed
US-6831088-B2 Wound healing agents; antiscarring agents PFIZER INC. 2004-12-14 — — US disclosed
US-6821972-B2 ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS PFIZER INC. 2004-11-23 — — US disclosed
US-20040142986-A1 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors DATTA USA (GB) 2004-07-22 — — US disclosed
US-20030119807-A1 3-Heterocyclylpropanohydroxamic acids BAILEY SIMON (US) 2003-06-26 — — US disclosed
US-20030069291-A1 3-heterocyclylpropanohydroxamic acid PCP inhibitors PFIZER INC. 2003-04-10 — — US disclosed
US-20020188121-A1 Novel olefination process to itaconate and succinate derivatives DERRICK ANDREW MICHAEL (GB) 2002-12-12 — — US disclosed
US-20020187979-A1 3-heterocyclylpropanohydroxamic acid PCP inhibitors FISH PAUL VINCENT (GB) 2002-12-12 — — US disclosed
US-20020151535-A1 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors PFIZER, INC 2002-10-17 — — US disclosed
US-6452041-B1 REACTING ALDEHYDE OF FORMULA RCHO, OR A PROTECTED DERIVATIVE THEREOF SUCH AS A HEMIACETAL OR ADDUCT THEREOF SUCH AS A BISULPHITE, WITH A PHOSPHORUS COMPOUND TO OBTAIN SUCCINATE OR ITACONATE DERIVATIVE PFIZER INC. 2002-09-17 — — US disclosed
US-6448278-B2 ANTISCARRING AGENT PFIZER INC. 2002-09-10 — — US disclosed
US-20010021718-A1 Procollagen C-proteinase inhibitors PFIZER INC. 2001-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020188121-A1 Novel olefination process to itaconate and succinate derivatives HOGA1, OGDH, HADHA EPHX1 2944/4885HDAC4 335/4885HDAC1 387/4885
US-20010021718-A1 Procollagen C-proteinase inhibitors MMP1, CTSL, PREP EPHX1 755/4885HDAC4 1489/4885HDAC1 454/4885
US-20020187979-A1 3-heterocyclylpropanohydroxamic acid PCP inhibitors MMP1, CPA1, PAH EPHX1 75/4885HDAC4 1173/4885HDAC1 217/4885
US-20020151535-A1 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors ALPI, TIMP3, MMP1 EPHX1 147/4885HDAC4 2010/4885HDAC1 523/4885
US-20030119807-A1 3-Heterocyclylpropanohydroxamic acids CPA1, MMP1, PREP EPHX1 115/4885HDAC4 1030/4885HDAC1 317/4885
US-20040142986-A1 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors ALPI, TIMP3, MMP1 EPHX1 147/4885HDAC4 2010/4885HDAC1 523/4885
US-20030069291-A1 3-heterocyclylpropanohydroxamic acid PCP inhibitors PAH, CYP2F1, CYP7A1 EPHX1 37/4885HDAC4 2008/4885HDAC1 593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.